TY - JOUR
T1 - Similar long-term outcome of dissimilar drug-eluting stents
T2 - Is it time to change the assessment?
AU - von Birgelen, Clemens
AU - Ploumen, Eline H.
N1 - Funding Information:
C. von Birgelen reports that the Research Department of Thoraxcentrum Twente received institutional research grants provided by Abbott Vascular, Biotronik, Boston Scientific, and Medtronic.
PY - 2021/4
Y1 - 2021/4
N2 - Long-term follow-up of randomised drug-eluting stent (DES) trials provides information that may be of great clinical value. While restenosis in DES generally occurs within the first two years, some safety and efficacy endpoints may only be seen at later stages. Most randomised trials that compared contemporary DES using Kaplan-Meier methods showed no significant difference in long-term outcome despite substantial between-DES differences in strut thickness, polymer type, stent design, and drug1,2,3. However, the inability to prove a difference is not the same as proof of no difference. In case of a negative trial result, in principle, there may be truly ...
AB - Long-term follow-up of randomised drug-eluting stent (DES) trials provides information that may be of great clinical value. While restenosis in DES generally occurs within the first two years, some safety and efficacy endpoints may only be seen at later stages. Most randomised trials that compared contemporary DES using Kaplan-Meier methods showed no significant difference in long-term outcome despite substantial between-DES differences in strut thickness, polymer type, stent design, and drug1,2,3. However, the inability to prove a difference is not the same as proof of no difference. In case of a negative trial result, in principle, there may be truly ...
UR - http://www.scopus.com/inward/record.url?scp=85103744008&partnerID=8YFLogxK
U2 - 10.4244/EIJV16I18A266
DO - 10.4244/EIJV16I18A266
M3 - Editorial
C2 - 33792543
AN - SCOPUS:85103744008
SN - 1774-024X
VL - 16
SP - E1468-E1469
JO - EuroIntervention
JF - EuroIntervention
IS - 18
ER -